VINELAND — City Council on Tuesday authorized $2.6 million in loans to help a pharmaceutical manufacturing company open on West Elmer Road.

The Urban Enterprise Zone loans will give Phusion Labs Manufacturing Inc. some financing for property acquisition, equipment purchases and business start-up costs.

Phusion Labs will make a variation of the Cold-EEZE cold remedy in an almost 31,000-square-foot building that used to house a German-based company which made a vitamin C product. Phusion Labs will hire about 25 to 30 people for jobs that range from packaging to high-tech laboratory work, city officials said.

Latest Video

City Council voted 4-0 to approve a pair of resolutions authorizing two UEZ loans. One loan is for $2 million, the second for $600,000.

UEZ money comes from state sales tax revenue. That money is used for economic development projects.

“I’m kind of excited about this,” City Councilman Douglas Albrecht said. “We’ve been fortunate to have a pharmaceutical company approach the city. They’re looking to grow. This speeds up their business cycle by about two years. Hopefully, we’ll have a business partner for years to come.”

The building that Phusion Labs will use also has the capability to expand by about 30,000 square feet, City Councilman Louis Cresci said.

City Economic Developer Director Sandra Forosisky said Phusion Labs is a wholly owned subsidiary of ProPhase Labs, a company based in Doylestown, Pa.

The company’s flagship brand is Cold-EEZE. The product is a zinc gluconate lozenge that company officials said helps to limit the duration and symptoms of colds.

Contact Thomas Barlas:


Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.